8-K: Canopy Growth Reports Q3 Fiscal 2024 Results: Revenue Growth and Margin Improvement

Canopy Growth achieved its third consecutive quarter of sequential revenue growth in its Canadian cannabis business and a record quarter for medical sales, alongside significant margin improvements.

Summary

• Canopy Growth Corporation announced its financial results for the third quarter of fiscal year 2024, ending December 31, 2023.
• The company reported a consolidated gross margin of 36%, with Canada cannabis gross margins improving to 28%, a significant increase from -11% in the same quarter of the previous year.
• Consolidated net revenue was $79 million, a 7% decrease year-over-year, but excluding the impact of a divestiture, revenue grew by 6%.
• Rest-of-World cannabis revenue increased by 81% year-over-year, driven by growth in Australia and Europe.
• Storz & Bickel net revenue increased 54% sequentially, boosted by the new VENTY vaporizer and strong Black Friday sales.
• Free cash flow from continuing operations improved to -$34 million, a 57% improvement year-over-year.
• The company reduced its overall debt by $69 million during the quarter and held a cash and short-term investments balance of $186 million as of December 31, 2023.
• Management reaffirmed its expectation to achieve positive Adjusted EBITDA in each business unit exiting fiscal year 2024.

Sentiment

Score: 7

Explanation: The document presents a mixed picture with significant improvements in profitability and cash flow, but also a decline in overall revenue. The positive outlook and strategic moves towards the US market are encouraging, but the company still faces challenges. The sentiment is cautiously optimistic.

Positives

• The company achieved its third consecutive quarter of sequential revenue growth in its Canadian cannabis business.
• Canada medical cannabis net revenue increased by 11% year-over-year, achieving a record quarter.
• The company has seen significant improvement in profitability and reduction in cash burn compared to the previous year.
• The company's right-sized business is consistently delivering profitability improvements and sequential growth.
• The company is focused on cannabis and demonstrating growth across all business units.
• The company's Canopy USA strategy is moving forward, with a special shareholder meeting scheduled for April 12, 2024.
• The company has added over 900 points of distribution nationally for flower in Q3 FY2024.
• The re-introduction of Wana brand cannabis edibles has re-established robust distribution nationally.
• The company's Australian medical cannabis business has generated 12 straight quarters of revenue growth.
• The new Storz & Bickel Venty portable vaporizer has exceeded expectations, leading to a second production shift.

Negatives

• Consolidated net revenue decreased by 7% year-over-year to $79 million.
• The company reported a net loss from continuing operations of $230.3 million.
• The company's free cash flow from continuing operations was negative at -$34 million.
• Selling, general and administrative expenses were $54 million in Q3 FY2024, although down from $90 million in Q3 FY2023.
• The company reported an operating loss from continuing operations of $60 million in Q3 FY2024.

Risks

• The company faces risks related to the successful execution of its Canopy USA strategy.
• There are risks associated with the special shareholder meeting and the creation of exchangeable shares.
• The company is subject to regulatory risks in the cannabis industry, including changes in laws and regulations.
• The company faces risks related to its ability to refinance debt and comply with debt covenants.
• There are risks associated with the company's ability to achieve positive Adjusted EBITDA in each business unit exiting FY2024.
• The company faces risks related to the ongoing impact of the legalization of cannabis and the development of regulations.
• The company faces risks related to competition in the cannabis industry.
• The company faces risks related to its ability to manage disruptions in credit markets or changes to its credit ratings.
• The company faces risks related to the long term macroeconomic effects of the COVID-19 pandemic and any future pandemic or epidemic.

Future Outlook

Management reaffirms expectation to achieve positive Adjusted EBITDA in each business unit exiting FY2024 and expects to be the first and only U.S. listed company offering shareholders a unique opportunity to gain exposure to the fastest growing cannabis market in the world through its Canopy USA strategy.

Management Comments

• David Klein, Chief Executive Officer, stated that the company is singularly focused on cannabis and demonstrating growth across all business units.
• David Klein also mentioned that with the Canopy USA strategy moving forward, they expect to be the first and only U.S. listed company offering shareholders a unique opportunity to gain exposure to the fastest growing cannabis market in the world.
• Judy Hong, Chief Financial Officer, noted that the Q3 FY2024 results demonstrate substantial improvement in profitability and reduction in cash burn compared to the previous year and Q2 FY2024.
• Judy Hong also stated that the company's right-sized business is consistently delivering profitability improvements as well as sequential growth.

Industry Context

This announcement comes as the cannabis industry continues to evolve, with companies focusing on profitability and strategic growth. Canopy Growth's focus on the U.S. market through its Canopy USA strategy aligns with the trend of companies seeking opportunities in the rapidly expanding U.S. cannabis sector. The company's improved margins and reduced cash burn are positive signs in a competitive market.

Comparison to Industry Standards

• Canopy Growth's gross margin of 36% is a significant improvement compared to its own performance in the previous year, but it is important to compare this to other cannabis companies.
• For example, Tilray Brands, another major cannabis player, has reported gross margins in the 20-30% range in recent quarters, suggesting Canopy's performance is relatively strong in this area.
• However, companies like Curaleaf have reported gross margins closer to 40-50%, indicating that there is still room for improvement for Canopy Growth.
• In terms of revenue growth, Canopy's 6% growth (excluding divestiture impacts) is moderate compared to some of the faster-growing U.S. multi-state operators (MSOs), which have seen double-digit growth rates.
• For example, Trulieve and Green Thumb Industries have consistently reported higher revenue growth rates, highlighting the competitive landscape.
• The 81% growth in Rest-of-World cannabis revenue is a positive sign, but it is important to note that this segment is still smaller than the Canadian market for Canopy.
• The improvement in free cash flow is a positive development, but the company still needs to achieve positive cash flow to ensure long-term sustainability.
• Compared to other Canadian LPs, Canopy's focus on profitability and strategic growth in the US market is a common theme, but the execution and results vary significantly between companies.

Management Changes

Stakeholder Impact

• Shareholders are expected to have an opportunity to participate in the U.S. cannabis market through Canopy Growth's non-controlling interest in Canopy USA.
• Employees may be impacted by the company's restructuring actions and cost reduction efforts.
• Customers will benefit from the company's focus on quality products and innovative offerings.
• Suppliers may be impacted by the company's cost reduction initiatives.
• Creditors will be impacted by the company's debt reduction efforts.

Next Steps

• The company expects to file its definitive proxy statement with the SEC on or about February 13, 2024.
• A special shareholder meeting is scheduled for April 12, 2024, to vote on the creation of exchangeable shares.
• The company will continue to execute its Canopy USA strategy.
• The company will continue to focus on achieving positive Adjusted EBITDA in each business unit exiting FY2024.

Key Dates

Keywords

cannabis, Canopy Growth, financial results, revenue, gross margin, EBITDA, medical cannabis, adult-use cannabis, Storz & Bickel, vaporizer, Canopy USA, debt reduction